Crossword Solver > found answer > NAPHTHYLAMI

Welcome to Anagrammer Crossword Genius! Keep reading below to see if naphthylami is an answer to any crossword puzzle or word game (Scrabble, Words With Friends etc). Scroll down to see all the info we have compiled on naphthylami.

CROSSWORD
ANSWER

naphthylami

Searching in Crosswords ...

The answer NAPHTHYLAMI has 0 possible clue(s) in existing crosswords.

Searching in Word Games ...

The word NAPHTHYLAMI is NOT valid in any word game. (Sorry, you cannot play NAPHTHYLAMI in Scrabble, Words With Friends etc)

There are 11 letters in NAPHTHYLAMI ( A¹H⁴I¹L¹M³N¹P³T¹Y⁴ )

To search all scrabble anagrams of NAPHTHYLAMI, to go: NAPHTHYLAMI

Rearrange the letters in NAPHTHYLAMI and see some winning combinations

6 letters out of NAPHTHYLAMI

5 letters out of NAPHTHYLAMI

4 letters out of NAPHTHYLAMI

3 letters out of NAPHTHYLAMI

AAH AAL AHA AHI AIL AIM AIN AIT ALA ALP ALT AMA AMI AMP ANA ANI ANT ANY APT HAH HAM HAP HAT HAY HIM HIN HIP HIT HYP IMP LAM LAP LAT LAY LIN LIP LIT MAN MAP MAT MAY MIL NAH NAM NAP NAY NIL NIM NIP NIT NTH PAH PAL PAM PAN PAT PAY PHI PHT PIA PIN PIT PLY PYA TAM TAN TAP THY TIL TIN TIP YAH YAM YAP YIN YIP

2 letters out of NAPHTHYLAMI

AA AH AI AL AM AN AT AY HA HI HM IN IT LA LI MA MI MY NA PA PI TA TI YA

Searching in Dictionaries ...

Definitions of naphthylami in various dictionaries:

No definitions found

Word Research / Anagrams and more ...

Keep reading for additional results and analysis below.

Naphthylami might refer to
Naphthylisopropylamine (PAL-287) is an experimental drug currently under investigation for the treatment of alcohol and stimulant addiction.Naphthylisopropylamine acts as a non-neurotoxic releasing agent of serotonin, norepinephrine, and dopamine, with EC50 values of 3.4 nM, 11.1 nM, and 12.6 nM, respectively. It also has affinity for the 5-HT2A, 5-HT2B, and 5-HT2C receptors (EC50 values = 466 nM, 40 nM, and 2.3 nM, respectively), and acts as a full agonist at 5-HT2B and as a partial agonist at 5-HT2C, while its affinity for 5-HT2A is probably too low to be significant.In animal studies, naphthylisopropylamine was shown to reduce cocaine self-administration, yet produced relatively weak stimulant effects when administered alone, being a (much) lesser stimulant than d-amphetamine for comparison. Further research is now being conducted in primates to see if it will be a useful substitute for treating drug addiction in humans as well.An important observation is that in behavioral studies, rodents would consistently self-administer selective norepinephrine and dopamine releasing agents such as d-amphetamine, yet compounds that also release serotonin like naphthylisopropylamine would not be self-administered. In addition to the drugs (acute) effects on self-administration, all of the available evidence suggests that the locomotor activation caused by the majority of dopamine releasers is also dampened when the drugs also cause serotonergic release. In fact, PAL-287 causes no locomotor activation at all (although admittedly the tests were only after acute dosing). * The high affinity of PAL-287 for 5-HT2C receptors meant that it functioned as a reliable anorectant and was being considered for this indication (i.e. weight loss). However, there were ultimately some concerns raised over the compounds affinity for 5HT2B receptors, since some of the more serious side effects of the serotonin releasing weight loss drug fenfluramine were linked to an activation of this receptor. Apparently, more research will have to be done to assess if PAL-287 causes activation of the 5HT2A and 5HT2B receptors in vivo. However, according to the authors, even the relatively safe drug MDMA causes heart disease, and the incidence being reported for fenfluramine was not that great, even though the evidence being presented was indisputable. Thus it is relatively more likely that any of the more serious side effects from using PAL-287 will only occur in cases of overdose, and not when using a clinically responsible amount of the drug.

Naphthylami might refer to

Naphthylisopropylamine (PAL-287) is an experimental drug currently under investigation for the treatment of alcohol and stimulant addiction.Naphthylisopropylamine acts as a non-neurotoxic releasing agent of serotonin, norepinephrine, and dopamine, with EC50 values of 3.4 nM, 11.1 nM, and 12.6 nM, respectively. It also has affinity for the 5-HT2A, 5-HT2B, and 5-HT2C receptors (EC50 values = 466 nM, 40 nM, and 2.3 nM, respectively), and acts as a full agonist at 5-HT2B and as a partial agonist at 5-HT2C, while its affinity for 5-HT2A is probably too low to be significant.In animal studies, naphthylisopropylamine was shown to reduce cocaine self-administration, yet produced relatively weak stimulant effects when administered alone, being a (much) lesser stimulant than d-amphetamine for comparison. Further research is now being conducted in primates to see if it will be a useful substitute for treating drug addiction in humans as well.An important observation is that in behavioral studies, rodents would consistently self-administer selective norepinephrine and dopamine releasing agents such as d-amphetamine, yet compounds that also release serotonin like naphthylisopropylamine would not be self-administered. In addition to the drugs (acute) effects on self-administration, all of the available evidence suggests that the locomotor activation caused by the majority of dopamine releasers is also dampened when the drugs also cause serotonergic release. In fact, PAL-287 causes no locomotor activation at all (although admittedly the tests were only after acute dosing).
* The high affinity of PAL-287 for 5-HT2C receptors meant that it functioned as a reliable anorectant and was being considered for this indication (i.e. weight loss). However, there were ultimately some concerns raised over the compounds affinity for 5HT2B receptors, since some of the more serious side effects of the serotonin releasing weight loss drug fenfluramine were linked to an activation of this receptor. Apparently, more research will have to be done to assess if PAL-287 causes activation of the 5HT2A and 5HT2B receptors in vivo. However, according to the authors, even the relatively safe drug MDMA causes heart disease, and the incidence being reported for fenfluramine was not that great, even though the evidence being presented was indisputable. Thus it is relatively more likely that any of the more serious side effects from using PAL-287 will only occur in cases of overdose, and not when using a clinically responsible amount of the drug.

Anagrammer Crossword Solver is a powerful crossword puzzle resource site. We maintain millions of regularly updated crossword solutions, clues and answers of almost every popular crossword puzzle and word game out there. We encourage you to bookmark our puzzle solver as well as the other word solvers throughout our site. Explore deeper into our site and you will find many educational tools, flash cards and plenty more resources that will make you a much better player. Naphthylami: Naphthylisopropylamine (PAL-287) is an experimental drug currently under investigation for the treat...